Nico J. Seidler

Nico J. Seidler

Auto-generated profile, based on publicly available information

Nico J. Seidler

Department of Chemistry College of Arts and Sciences University at Buffalo The State University of New York Buffalo New York USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2023 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
VWValentin R Wydra
Valentin R Wydra
RDRaphael B Ditzinger
Raphael B Ditzinger
NSNico J Seidler
Nico J Seidler
FHFrederik W Hacker
Frederik W Hacker
SLStefan Laufer
Stefan Laufer
The mitogen-activated protein kinase (MAPK) family consist of p38 MAP kinases, c-Jun N-terminal kinases (JNKs) and extracellular signal-regulated kinases (ERKs). They are involved in a multitude of diseases, including inflammatory, autoimmune, neurodegenerative, and metabolic diseases as well as cancer. In recent years, further developments in the field of MAPK-inhibitors have been reported, including an isoform or downstream target selective inhibition of MAPKs as well as target protein degradation approaches. This review summarizes newly patented MAPK-inhibitors that were claimed between 2018 and early 2023. Presented are the patents as well as their corresponding publications, the storyline of development, and clinical trials involving these compounds. This article elaborates a total of 27 patents, which were identified using established search engines. Although industrial research on MAPK-inhibitors has been ongoing for more than 20 years, novel clinical trials of MAPK-inhibitors as potential drug candidates are still being conducted in the period under review. Recently reported inhibitors show an excellent selectivity profile and are even achieving selectivity between closely related isoforms. This progression offers the possibility to eliminate unwanted side effects and may finally lead to the approval of the first MAPK-inhibitor.

13 January 2025 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
GWGuiqun Wang
Guiqun Wang
NSNico J. Seidler
Nico J. Seidler
SRSandra Röhm
Sandra Röhm
YPYufeng Pan
Yufeng Pan
XLXiaojun Julia Liang
Xiaojun Julia Liang
SKStefan Knapp
Stefan Knapp
Protein kinases are important drug targets, yet specific inhibitors have been developed for only a fraction of the more than 500 human kinases. A major challenge in designing inhibitors for highly related kinases is selectivity. Unlike their non‐covalent counterparts, covalent inhibitors offer the advantage of selectively targeting structurally similar kinases by modifying specific protein side chains, particularly non‐conserved cysteines. Previously, covalent fragment screens yielded potent and selective inhibitors for individual kinases such as ERK1/2 but have not been applied to the broader kinome. Furthermore, many of the accessible cysteine positions have not been addressed so far. Here, we outline a generalizable approach to sample ATP‐site cysteines with fragment‐like covalent inhibitors. We present the development of a kinase‐focused covalent fragment library and its systematic screening against a curated selection of 47 kinases, with 60 active site‐proximal cysteines using LC/MS and differential scanning fluorimetry (DSF) assays, followed by hit validation through various complementary techniques. Our findings expand the repertoire of targetable cysteines within protein kinases, provide insight into unique binding modes identified from crystal structures and deliver isoform‐specific hits with promising profiles as starting points for the development of highly potent and selective covalent inhibitors.

17 September 2026 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
NSNico J. Seidler
Nico J. Seidler
MMMonica R. MacDonald
Monica R. MacDonald
AMAthina A. Moschopoulou
Athina A. Moschopoulou
SCSahba Cunningham
Sahba Cunningham
TWTess M. Weber
Tess M. Weber
DHDavid E. Heppner
David E. Heppner
ZUSAMMENFASSUNG: Selektivität ist eine wichtige Anforderung in der Entwicklung von Kinase‐Inhibitoren und das Erreichen dieser stellt nach wie vor eine große Herausforderung dar. Um neue Wege zur Erzielung von Selektivität zu ebnen, haben wir den ersten p38δ‐Isoform‐selektiven Inhibitor entwickelt, welcher im Vergleich zu bisher existierenden Verbindungen 12000‐fach selektiver ist und zudem ein überlegenes Kinomprofil aufweist. Röntgen‐Kristallstrukturen zeigten, dass diese Moleküle nicht‐kanonische n‐π‐π‐Sandwich Wechselwirkungen eingehen, welche durch einen strukturellen Umbau des P‐loops ermöglicht werden. Strukturelle und funktionale Analyse offenbarte, dass es sich bei den Inhibitoren um sich selbsteinkapselnde Verbindungen handelt, welche aufgrund einer sterischen Kollision die Bindetasche verschließen. Diese Konformation wird durch ein Wasserstoffbrücken‐Netzwerk stabilisiert, welches die p38δ‐spezifische Aminosäure H30 beinhaltet. Diese Arbeit zeigt, wie die Selektivität von Inhibitoren durch gezielte Umgestaltung der Bindetasche erreicht wird, wobei strukturelle Merkmale außerhalb der Bindestelle genutzt werden, die häufig übersehen werden.

22 October 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
NSNico J. Seidler
Nico J. Seidler
MMMonica R. MacDonald
Monica R. MacDonald
AMAthina A. Moschopoulou
Athina A. Moschopoulou
SCSahba Cunningham
Sahba Cunningham
TWTess M. Weber
Tess M. Weber
DHDavid E. Heppner
David E. Heppner


15 September 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
NSNico J. Seidler
Nico J. Seidler
MMMonica R. MacDonald
Monica R. MacDonald
AMAthina A. Moschopoulou
Athina A. Moschopoulou
SCSahba Cunningham
Sahba Cunningham
TWTess M. Weber
Tess M. Weber
DHDavid E. Heppner
David E. Heppner
Rendering kinase inhibitors selective is a strict requirement in drug development and remains a persistent challenge. To identify new routes to engineer selectivity, we have discovered a first‐in‐class p38δ‐isoform selective inhibitor reflecting 12 000‐fold selectivity improvement over currently available compounds and superior kinome targeting. X‐ray crystallographic characterization indicates that these molecules bind through noncanonical n–π–π stacking sandwich interactions enabled by structural remodeling of the P‐loop. Structural and functional analysis indicates that these selective inhibitors are self‐encapsulating agents due to direct steric clashing that occludes the binding site in a conformation reinforced by a hydrogen‐bonding network involving p38δ‐unique H30. This work reveals how inhibitor selectivity is achieved by deliberate remodeling of the drug binding site leveraging structural features outside the binding site commonly overlooked in structure‐guided design.